Professor Shudong Wang’s research focuses on drug discovery in several therapeutic areas, especially cancer. She is particularly interested in forging multidisciplinary approaches for drug discovery translational research.
After received her Ph.D. in 1998 Shudong spent seven years in a British pharmaceutical company (Cyclacel Inc., NASDAQGM:CYCC). As head of Chemistry and programme manager (2000-2005) she helped to establish medicinal chemistry and drug discovery capability of the company. She played a leading role in several projects that reached preclinical and clinical stages.
In 2005, Shudong joined the University of Nottingham as Reader in Medicinal Chemistry at School of Pharmacy, the top pharmacy school in the United... Read more
About me
Professor Shudong Wang’s research focuses on drug discovery in several therapeutic areas, especially cancer. She is particularly interested in forging multidisciplinary approaches for drug discovery translational research.
After received her Ph.D. in 1998 Shudong spent seven years in a British pharmaceutical company (Cyclacel Inc., NASDAQGM:CYCC). As head of Chemistry and programme manager (2000-2005) she helped to establish medicinal chemistry and drug discovery capability of the company. She played a leading role in several projects that reached preclinical and clinical stages.
In 2005, Shudong joined the University of Nottingham as Reader in Medicinal Chemistry at School of Pharmacy, the top pharmacy school in the United Kingdom. During the six years (2005-2011) she has built up a strong multi-disciplinary team, composed of medicinal chemistry, biology and pharmacology, which has enabled her team to conduct world-class drug discovery research. Several kinase inhibitor drug leads reached the late preclinical development stage.
In December 2011 Professor Wang relocated to the University of South Australia. As Chair of Medicinal Chemistry at School of Pharmacy and Medical Sciences, she has now established the drug discovery and cancer research capabilities. Her research activities are directed towards development of new drug candidates for kinases-targeted cancer therapies. These involve structure- and target-guided design and synthesis of compound libraries that are used to characterise the cellular consequences associated with the diseases. The strategy holds promise for rapid advancement of drug discovery in an effort to identify both drug candidates and novel therapeutic targets.
With major interests in original and innovative drug discovery, Professor Wang has demonstrated sustained translational research that is highlighted by a portfolio of over 85 patent applications, and has achieved extensive success in commercialisation from her research. Her research profile has led to a number of collaborations with world-class research teams in Australian, China, Germany, Hong Kong, Netherlands, UK, and USA. She has been an advisor for several biotech and pharma drug discovery programmes and has established strong links with drug industry.
About me
About me
Doctor of Philosophy Central Queensland University
Master of Philosophy University of Southern Queesland
Bachelor of Science Sichuan University, China
Professor Wang current research is focussed on the discovery and development of novel protein kinase inhibitor drugs for treatment of cancers. The current ongoing research programmes include:
Research
Excludes commercial-in-confidence projects.
Development of a novel and highly selective CDK4/6 inhibitor for treating cancer, NHMRC - Development Grant, 01/01/2018 - 30/04/2022
Discovery and development of CDK 4/6 inhibitors as anti-cancer agents, Changzhou Qianhong Bio-pharma Co Ltd, 12/12/2016 - 11/12/2021
Targeting cyclin-dependent kinase 4 in glioblastoma, Neurosurgical Research Foundation, 24/08/2020 - 21/08/2021
Development of CDK9 inhibitors for treatment of acute myeloid leukaemia, Bio Innovation SA, 01/06/2016 - 30/09/2018
Development of a new and effective therapeutic agent to treat childhood leukemia, Tour de Cure Ltd, 14/10/2016 - 30/06/2018
Novel inhibitors of map kinase-interacting kinase for cancer treatment, Cancer Council SA - Beat Cancer Fellowship, 03/01/2013 - 31/03/2017
Discovery of CDK6 inhibitors for treatment of childhood medulloblastoma, Channel 7 Children's Research Foundation of SA, 01/01/2015 - 31/12/2016
New treatment for childhood leukaemia, Channel 7 Children's Research Foundation of SA, 01/01/2016 - 31/12/2016
Pharmacological inhibitors of Mnk for the treatment of cancer, NHMRC - Project Grant, 01/01/2013 - 31/08/2016
Independent Validation and Investor Readiness for Cyclin-Dependent Kinase (CDK9), Bio Innovation SA, 01/01/2016 - 30/08/2016
CDK9 Inhibitors for the treatment of castration resistant prostate cancer, Cancer Council SA - Beat Cancer, 01/01/2015 - 31/12/2015
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2023 |
2
2
11
|
2023 |
1
1
1
|
2023 |
Open access
3
|
2023 |
1
|
2023 |
Open access
|
2022 |
Open access
3
2
2
|
2022 |
Open access
2
2
9
|
2022 |
12
12
100
|
2022 |
3
2
2
|
2022 |
Open access
12
11
2
|
2021 |
Open access
7
8
|
2021 |
Open access
46
34
2
|
2021 |
5
5
37
|
2021 |
Open access
6
6
1
|
2021 |
8
8
1
|
2021 |
Open access
4
3
|
2021 |
Open access
10
7
1
|
2020 |
8
10
1
|
2020 |
37
32
7
|
2020 |
Open access
17
17
|
2020 |
Open access
11
8
1
|
2020 |
Open access
6
5
1
|
2020 |
Open access
121
98
14
|
2020 |
Open access
7
4
5
|
2019 |
6
5
|
2019 |
Open access
9
7
3
|
2019 |
Open access
16
16
1
|
2019 |
Open access
96
83
8
|
2019 |
Open access
34
30
|
2019 |
24
20
3
|
2019 |
143
133
10
|
2018 |
73
67
8
|
2018 |
Open access
16
16
3
|
2017 |
7
7
1
|
2017 |
Open access
22
18
|
2017 |
14
15
2
|
2017 |
Open access
32
29
|
2017 |
Open access
22
19
3
|
2017 |
Open access
10
10
2
|
2017 |
Open access
54
48
6
|
2016 |
41
40
|
2016 |
52
49
16
|
2016 |
19
18
|
2016 |
Open access
21
20
|
2016 |
12
12
|
2016 |
Open access
50
46
5
|
2016 |
Open access
9
8
1
|
2016 |
Open access
29
30
14
|
2015 |
Open access
|
2015 |
7
8
1
|
2015 |
34
33
11
|
2015 |
Open access
21
15
7
|
2015 |
Open access
15
15
|
2015 |
Open access
25
22
6
|
2015 |
27
25
4
|
2015 |
33
33
3
|
2015 |
Open access
93
82
|
2014 |
Open access
81
74
10
|
2014 |
Open access
66
62
1
|
2014 |
Open access
46
44
3
|
2014 |
Open access
22
18
3
|
2014 |
40
36
6
|
2014 |
Open access
72
63
|
2013 |
Open access
10
9
|
2013 |
48
44
|
2013 |
Open access
109
108
7
|
2012 |
65
55
|
2012 |
Open access
46
44
|
2012 |
Open access
135
122
|
2012 |
10
6
|
2012 |
Open access
51
49
|
2012 |
65
57
|
2011 |
Open access
14
14
|
2011 |
18
13
|
2011 |
106
102
|
2010 |
16
14
|
2010 |
31
31
|
2010 |
Open access
93
85
|
2010 |
Open access
89
80
|
2009 |
1
|
2009 |
10
7
|
2008 |
193
|
1. S. Diab, A. M Abdelaziz, P. Li, T. Teo, S.K C. Basnet, B. Noll, M. H Rahaman, J. Lu, J. Hou, M. Yu, B. T. Le, H. Albrecht, R. W Milne and S. Wang. Dual Inhibition of Mnk2 and FLT3 for Potential Treatment of Acute MyeloidLeukaemia. European Journal of Medicinal Chemistry, 2017, DOI: 10.1016/j.ejmech.2017.08.006, in press.
2. J. L Lenjisa, S. Tadesse, N. Z Khair, M. Kumarasiri, M. Yu, H. Albrecht, R. Milne, and S. Wang. CDK5 in Oncology: Recent Advances and Future Prospects. Future Medicinal Chemistry. Accepted 8th June 2017.
3. S.Tadesse, L. Bantie, K. Tomusange, M. Yu, S. Islam, N. Bykovska, B. Noll, G. Zhu, P. Li, F. Lam, M. Kumarasiri, R. Milne and S. Wang. Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents. British Journal of Pharmacology, 2017, in press.
4. S.Tadesse, G. Zhu, L. B Mekonnen, J. L Lenjisa, M. Yu, M. P. Brown, and S. Wang. A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. Future Medicinal Chemistry. 2017, In press.
5. S. Tadesse, M.Yu, L. B. Mekonnen, F. Lam, S. Islam, K. Tomusange, M. H. Rahaman, B. Noll, S. K. C. Basnet, T. Teo, H. Albrecht, R. Milne, and S. Wang. Highly Potent, Selective, and Orally Bioavailable 4‑Thiazol‑N‑(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation. Journal of Medicinal Chemistry, 60, 1892−1915, 2017.
5. M. Kumarasiri, T. Teo, M. Yu, S. Philip, S.K. C. Basnet, H. Albrecht, M. J. Sykes, P. Wang, and S. Wang. In Search of Novel CDK8 Inhibitors by Virtual Screening. Journal of Chemical Information and Modeling, 57 (3), pp 413–416, 2017.
Research
Professor Wang current research is focussed on the discovery and development of novel protein kinase inhibitor drugs for treatment of cancers. The current ongoing research programmes include:
Research
Details | Registry | Status |
---|---|---|
Wang, Shudong; Goh, Aik Wye |
World | Granted |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds Wang, Shudong; Zeleke, Solomon Tadesse; Yu, Mingfeng |
WO | Filed |
External engagement & recognition
Organisation | Country |
---|---|
Adelaide Oncology and Haematology | AUSTRALIA |
Ain Shams University | EGYPT |
Cardiff University | UNITED KINGDOM |
Children's Hospital Zurich | SWITZERLAND |
Chinese Academy of Sciences | CHINA |
Cresset Discovery | UNITED KINGDOM |
CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
Cyclacel Pharmaceuticals, Inc | UNITED KINGDOM |
East China University of Science and Technology | CHINA |
Essen University Hospital | GERMANY |
Garvan Institute of Medical Research | AUSTRALIA |
German Cancer Research Center | GERMANY |
GlaxoSmithKline | AUSTRALIA |
Goethe University Frankfurt | GERMANY |
Lebanese American University | LEBANON |
National Organization for Drug Control and Research | EGYPT |
National Research Centre | EGYPT |
Newcastle University, United Kingdom | UNITED KINGDOM |
Open University | UNITED KINGDOM |
Peter MacCallum Cancer Centre | AUSTRALIA |
RMIT University | AUSTRALIA |
Royal Prince Alfred Hospital | AUSTRALIA |
Shandong University | CHINA |
Shanghai Children's Medical Center | CHINA |
Shanghai Jiao Tong University | CHINA |
South Australian Health and Medical Research Institute (SAHMRI) | AUSTRALIA |
Sydney Children's Hospital | AUSTRALIA |
Technical University Munich | GERMANY |
The Kinghorn Cancer Centre | AUSTRALIA |
Topharman Shanghai Co. Ltd | UNITED STATES |
University of Adelaide | AUSTRALIA |
University of Birmingham | UNITED KINGDOM |
University of New South Wales | AUSTRALIA |
University of Newcastle | AUSTRALIA |
University of Nottingham | UNITED KINGDOM |
University of Oxford | UNITED KINGDOM |
University of South Australia | AUSTRALIA |
University Of South Carolina - Columbia | UNITED STATES |
University of Southampton | UNITED KINGDOM |
University of St Andrews | UNITED KINGDOM |
University of Sussex | UNITED KINGDOM |
University of Sydney | AUSTRALIA |
University of Toronto | CANADA |
Yabao Pharmaceutical Group Co., Ltd | CHINA |
Zhejiang Chinese Medical University | CHINA |
Zhejiang University | CHINA |
External engagement & recognition
Engagement/recognition | Year |
---|---|
FellowRoyal Society of Chemistry |
2018 |
MemberRoyal Australian Chemical Institute |
2018 |
MemberAmerican Association for Cancer Research (AACR) |
2018 |
MemberAmerican Chemical Society (ACS) |
2018 |
FellowRoyal Society of Chemistry |
2017 |
MemberRoyal Australian Chemical Institute |
2017 |
MemberAmerican Association for Cancer Research (AACR) |
2017 |
MemberAmerican Chemical Society (ACS) |
2017 |
Recipient, Top Development Grant for 2017Annual Research Excellence Awards, National Health and Medical Research Council (NHMRC) |
2017 |
Principle Cancer Research FellowshipCancer Council SA |
2013 |
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
CDK inhibitors as immunotherapeutic agents for cancer treatment | Current |
Design and synthesis of mnk Inhibitors for targeted cancer therapy | Current |
Development of Cyclin Dependent Kinase Inhibitors for Cancer Treatment | Current |
Evaluation of the cyclin-dependent kinase CDK inhibitors resistance for cancer treatment | Current |
Identification and preclinical evaluation of kinase-targeted drugs for repurposing in cancer | Current |
Identification of the mechanism of resistance against PI3K inhibitors in human leukemia | Current |
Investigating the role of novel Tropomyosin receptor kinase (TRK) inhibitor for the treatment of NTRK fusion-positive lung cancer | Current |
Preclinical evaluation of TAM kinase inhibitors as potential anticancer agents | Current |
Targeting tankyrases for the treatment of cancer | Current |
A combined lipophilic prodrug and lipid-based drug delivery approach to enable oral chemotherapy (with SN38) | Completed |
Derivatives of 4-(1H-pyrazol-4-yl)pyrimidine CDK2 inhibitors as potential anticancer agents: design, synthesis & evaluation | Completed |
Design, synthesis, and evaluation of novel CDK2 inhibitors as potential anticancer agents | Completed |
Developing inhibitorsof MAP kinase-interacting kinases as potential anti-cancer agents | Completed |
Development of cyclin dependent kinase 9 inhibitors for the treatment of cancer | Completed |
Discovery and evaluation of MNK inhibitors as potential anti-cancer agents | Completed |
Discovery and evaluation of styrylsulfonyl-methylpyridine derivatives as anticancer agents | Completed |
Discovery of cyclin-dependent kinase 2/5 inhibitors for the potential treatment of cancer | Completed |
Discovery of novel cyclin-dependent kinase 8 inhibitors as potential antitumour agents | Completed |
Discovery of novel inhibitors of MAPK-interacting kinases as anti-tumour agents | Completed |
Discovery of protein kinase inhibitors as potential anti-cancer agents | Completed |
Identification and characterisation of Mnk inhibitors as potential anti-cancer agents | Completed |
Investigating a novel CDK9 Inhibitor, CDKI-73, as a treatment for AML | Completed |
Novel cyclin-dependent kinase 9 inhibitors for the treatment of cancer: identification and preclinical evaluation | Completed |
Novel inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents: design, synthesis and evaluation | Completed |
Pharmacological evaluation of protein kinase inhibitors as anti-cancer agents | Completed |
Polymeric micelles to improve the delivery of poorly soluble antimicrobial agents to bacterial and fungal biofilms | Completed |
Pre-clinical development of a CDK inhibitor for the treatment of cancer | Completed |
Pre-clinical Evaluation of FLT3 Inhibitors for Treatment of Acute Myeloid Leukaemia | Completed |
Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer | Completed |
Preclinical evaluation of novel dual CDK2/5 inhibitors as anticancer drug candidates | Completed |
Protein kinase inhibitors as potential anti-cancer agents: design, synthesis and evaluation | Completed |